Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived pharmaceuticals. Established in 2002, the company specializes in addressing urinary system diseases, targeting markets in the United States, European Union, and Asia, with a particular emphasis on Taiwan and mainland China. Jyong Biotech’s pipeline includes drug candidates for conditions such as benign prostate hyperplasia, lower urinary tract symptoms, prostate cancer prevention, and interstitial cystitis. Notably, its lead candidate MCS-2 has been submitted for regulatory approval in the United States. The company’s vertically integrated model spans early-stage drug discovery, clinical development, regulatory affairs, manufacturing, and commercialization. Through its proprietary R&D platform, Jyong Biotech aims to deliver safe, effective, and differentiated botanical therapies, playing a distinctive role in advancing treatments for urological disorders and meeting unmet medical needs in global healthcare markets.